Stockreport

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

NRX Pharmaceuticals, Inc.  (NRXP) 
PDF -- 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with per share improvement in negative earnings. Additions to wor [Read more]